3Daughters is a Mansfield, MA–based clinical development company focused on evolutionary healthcare for women. Its technology platform uses physics and geometry to deliver targeted therapy to the uterus. The company's lead product, 3D-001, is a frameless, magnetic, non-hormonal intrauterine device (IUD) designed to conform to a woman's body for long-acting contraception. 3D-001 is paired with a patented Slider™ system for insertion and retrieval that aims to eliminate insertion steps and the nuisance of strings. 3Daughters plans an IND filing in early 2025 and expects to start a first-in-human Phase 1 study following IND approval. Financially, the company closed a $4.7M Seed round and has launched a $15M Series A to fund 3D-001's Phase 1 study. 3Daughters, based in Mansfield, MA and led by CEO Mary Beth Cicero, is developing women's healthcare technologies. Its lead product, 3D-001, is a frameless, magnetic, nonhormonal intrauterine device for long-acting contraception. 3D-001 is designed to conform to a woman's body and pairs with the company's patented Slider™ insertion/retrieval system intended for easier and less painful insertion and removal. The company emphasizes addressing longstanding, neglected issues such as IUD insertion pain. 3Daughters closed over $2M in a first tranche of Seed financing to advance its development plans. It intends to use the funds to complete an IND filing and initiate a Phase 1 clinical trial this year.

Total raised

$7M

Funding rounds

2

Latest round

Seed

Latest activity

Jul 2024